Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

596 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors.
Zindy P, Bergé Y, Allal B, Filleron T, Pierredon S, Cammas A, Beck S, Mhamdi L, Fan L, Favre G, Delord JP, Roché H, Dalenc F, Lacroix-Triki M, Vagner S. Zindy P, et al. Among authors: roche h. Cancer Res. 2011 Jun 15;71(12):4068-73. doi: 10.1158/0008-5472.CAN-11-0420. Epub 2011 Apr 15. Cancer Res. 2011. PMID: 21498638
Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis.
Dalenc F, Doisneau-Sixou SF, Allal BC, Marsili S, Lauwers-Cances V, Chaoui K, Schiltz O, Monsarrat B, Filleron T, Renée N, Malissein E, Meunier E, Favre G, Roché H. Dalenc F, et al. Among authors: roche h. Clin Cancer Res. 2010 Feb 15;16(4):1264-71. doi: 10.1158/1078-0432.CCR-09-1192. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145184 Clinical Trial.
[Breast cancer diagnostic assessment].
Dalenc F, Pons E, Roche H. Dalenc F, et al. Among authors: roche h. Rev Prat. 2017 Nov 20;67(9):e453-e454. Rev Prat. 2017. PMID: 30717583 French. No abstract available.
PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.
Jacot W, Dalenc F, Lopez-Crapez E, Chaltiel L, Durigova A, Gros N, Lozano N, Lacaze JL, Pouderoux S, Gladieff L, Romieu G, Roché H, Filleron T, Lamy PJ. Jacot W, et al. Among authors: roche h. Breast Cancer Res Treat. 2019 Oct;177(3):659-667. doi: 10.1007/s10549-019-05349-y. Epub 2019 Jul 11. Breast Cancer Res Treat. 2019. PMID: 31297647
The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Penault-Llorca F, Filleron T, Asselain B, Baehner FL, Fumoleau P, Lacroix-Triki M, Anderson JM, Yoshizawa C, Cherbavaz DB, Shak S, Roca L, Sagan C, Lemonnier J, Martin AL, Roché H. Penault-Llorca F, et al. Among authors: roche h. BMC Cancer. 2018 May 4;18(1):526. doi: 10.1186/s12885-018-4331-8. BMC Cancer. 2018. PMID: 29728098 Free PMC article.
596 results